Phase I (Safety Assessment) Of Durvalumab (Medi4736) With Focal Sensitizing Radiotherapy In Platinum Resistant Ovarian, Primary Peritoneal Or Fallopian Tube Epithelial Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要